418 related articles for article (PubMed ID: 28086831)
1. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
Ayyagari VN; Hsieh TJ; Diaz-Sylvester PL; Brard L
BMC Cancer; 2017 Jan; 17(1):49. PubMed ID: 28086831
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
Ayyagari VN; Diaz-Sylvester PL; Hsieh TJ; Brard L
PLoS One; 2017; 12(9):e0185111. PubMed ID: 28931042
[TBL] [Abstract][Full Text] [Related]
3. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action.
Ayyagari VN; Brard L
BMC Cancer; 2014 Feb; 14():61. PubMed ID: 24495391
[TBL] [Abstract][Full Text] [Related]
4. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.
Ayyagari VN; Johnston NA; Brard L
Anticancer Drugs; 2016 Jul; 27(6):547-59. PubMed ID: 27058706
[TBL] [Abstract][Full Text] [Related]
6. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
8. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
10. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
11. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
[TBL] [Abstract][Full Text] [Related]
12. Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
Marverti G; Ligabue A; Guerrieri D; Paglietti G; Piras S; Costi MP; Farina D; Frassineti C; Monti MG; Moruzzi MS
Gynecol Oncol; 2010 May; 117(2):202-10. PubMed ID: 20031193
[TBL] [Abstract][Full Text] [Related]
13. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
Karaca B; Atmaca H; Bozkurt E; Kisim A; Uzunoglu S; Karabulut B; Sezgin C; Sanli UA; Uslu R
Mol Biol Rep; 2013 Jun; 40(6):3925-33. PubMed ID: 23269627
[TBL] [Abstract][Full Text] [Related]
14. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
16. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
Byun JM; Lee DS; Landen CN; Kim DH; Kim YN; Lee KB; Sung MS; Park SG; Jeong DH
Acta Oncol; 2019 Nov; 58(11):1594-1602. PubMed ID: 31257975
[No Abstract] [Full Text] [Related]
18. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
19. Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.
Kim KK; Lange TS; Singh RK; Brard L; Moore RG
BMC Cancer; 2012 Apr; 12():147. PubMed ID: 22502731
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]